Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA-Reference-Cited by-同舟云学术

Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA

Published:2021-08-20 Issue:6 Volume:32 Page:590-598
ISSN:1040-8738
Container-title:Current Opinion in Ophthalmology
language:en
Short-container-title:

Author:

Nanegrungsunk Onnisa,Bressler Neil M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference27 articles.

1. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema;Elman;Ophthalmology,2010

2. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema;Wells;N Engl J Med,2015

3. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE;Nguyen;Ophthalmology,2012

4. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies;Heier;Ophthalmology,2016

5. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial;Gross;JAMA,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: A Caveat About Financial Incentives for Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy;American Journal of Ophthalmology;2023-06

2. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials;Eye;2022-11-11

3. A Caveat About Financial Incentives for Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy;American Journal of Ophthalmology;2022-11

4. The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study;Ophthalmic Surgery, Lasers and Imaging Retina;2022-10

5. Emerging opportunities for C3 inhibition in the eye;Seminars in Immunology;2022-01